METHOD FOR PREDICTION OF NEOADJUVANT CHEMOTHERAPY EFFECTIVENESS IN PATIENTS WITH DISSEMINATED FORMS OF OVARIAN CANCER Russian patent published in 2017 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention can be used to predict the effectiveness of neoadjuvant chemotherapy (NACT) in patients with disseminated ovarian cancer. The volume of the ascitic fluid, the level of insulin-like factor I (IGF-I), and the PAPP-A metalloproteinase in the ascitic fluid are determined before treatment, as well as the PAPP-A level in the tumour homogenate, regression function is calculated by the formula: F=-27.4-28.6⋅X₁+13.8⋅X₂+44.9⋅X₃-7.46⋅X₄, where X₁ is the amount of ascitic fluid before treatment (1- up to 1000 ml, 2 - 1000 ml or more); X₂ is the level of RAPP-A metalloproteinase in the tumour tissue in ng/mg of protein; X₃ is the level of IGF-I in the ascitic fluid in ng/mg of protein; X₄ is the level of RAPP-A metalloproteinase in the ascitic fluid in ng/mg of protein. Then the probability P of the clinical response to NACT is calculated by the formula: where e is the base of the natural logarithm = 2.718, and at P≥0.5, the effect of NACT is ascertained, at a P<0.5, the lack of NACT effectiveness is ascertained.

EFFECT: higher prediction accuracy.

1 tbl, 2 ex